Uncategorized
VIDEO: Allegro Ophthalmics begins phase 2 study of Luminate for PVD
DENVER — At the Association for Research in Vision and Ophthalmology meeting here, Vicken Karageozian, MD, chief technical officer for Allegro Ophthalmics, discusses the phase 2 study of Luminate, Allegro’s integrin peptide therapy candidate for inducing posterior vitreous detachment in patients with non-proliferative diabetic retinopathy.